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Abstract
Background: The alarmin cytokines IL-25 and IL-33 are key promoters of type 2 inflammation. Basophils respond to
alarmin cytokines, however the relationship of these cytokines with basophil activation and recruitment in human
studies of allergic asthma has not been well characterized. This study investigated the effect of IL-25 and IL-33 on
basophils in a model of allergic asthma.
Methods: 10 mild allergic asthmatics underwent allergen and diluent inhalation challenges. Bone marrow aspirates
were collected at pre-challenge and 24 h (h) post challenge. Peripheral blood and sputum samples were collected
at pre-challenge, 7 h, and 24 h post-challenge to measure basophil expression of IL-17RB, ST2, and intracellular
IL-25. Freshly isolated peripheral blood basophils from allergic donors were incubated overnight with IL-25 and
IL-33, or sputum supernatant collected post-allergen to assess pro-inflammatory effects of mediators released in
the airways.
Results: There were increased percentage of basophils expressing IL-17RB, ST2, and intracellular IL-25 collected
from bone marrow, peripheral blood, and sputum after allergen inhalation challenge. In vitro stimulation with
IL-25 and IL-33 increased the percentage of basophils expressing intracellular type 2 cytokines and surface
activation markers, and primed eotaxin-induced migratory potential of basophils, which was mediated directly
through IL-17RB and ST2, respectively. Stimulation of basophils with sputum supernatants collected post-allergen
challenge up-regulated the percentage of basophils expressing markers of activation and intracellular type 2
cytokines, which was reversed following blockade of the common β chain (βc).
Conclusions: Our findings indicate that the alarmin cytokines IL-33 and IL-25 increase basophil activation and
migratory potential, and may pose as a novel therapeutic targets for the treatment of allergic asthma.
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Background
Asthma is a chronic respiratory disease characterized by
reversible airway obstruction, airway inflammation, and
airway hyperresponsiveness (AHR). There are numerous
causes of this disorder, and recent evidence indicates
that the alarmin cytokines IL-25 and IL-33 may play a
key role in promoting allergic asthma.
In mouse models, transgenic over-expression or ad-
ministration of IL-25 and IL-33 generates airway eosino-
philia, up-regulated Type 2 cytokine expression, elevated
serum IgE, AHR and mucus hypersecretion [1–6]. Con-
versely, neutralization of IL-25 and IL-33 leads to reduc-
tion of airway inflammation, IgE levels, Type 2 cytokine
expression, goblet cell hyperplasia, and AHR [7–10].
IL-25 and IL-33 have been shown to exert their effects
on progenitor cells, mast cells, granulocytes, lymphocytes
and dendritic cells [11–20]. In human studies of allergic
asthma, IL-33 and ST2 expression in serum, lung tissue
and BALF have found to be higher in asthmatics compared
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to healthy controls and correlate with asthma severity
[21–25]. Similarly, levels of IL-25 and IL-17RB mRNA ex-
pression are elevated in serum, bronchial mucosa and the
skin, which correlates with allergic disease severity [21–26].
Basophils are involved in the early asthmatic response
(EAR) of asthma, acting as potent sources of histamine
and cysteinyl leukotrienes, which contribute to broncho-
constriction. Emerging evidence suggests that basophils
have an important role in promoting delayed airway in-
flammation. Peripheral and airway basophils increase in
number and activation in the LAR following allergen in-
halation, and are a significant source of IL-4 and IL-13
[27–30]. We have previously reported that the percentage
of basophils expressing surface activation markers, intra-
cellular cytokines (IL-4; IL-13) and TSLPR, significantly
increase in peripheral blood and sputum post-allergen in-
halation in mild allergic asthmatics for up to 24 h [28].
We have also shown in vitro that TSLP can promote hu-
man basophil pro-inflammatory activity and prime migra-
tory potential to eotaxin [28]. Despite these findings, it is
not well known what factors promote basophil lung-
homing and effector activity during the LAR, but reports
suggest that alarmin cytokines may play a role in regulat-
ing basophil activity. Protein and mRNA expression of
ST2 and sST2 have been confirmed on basophils, and be-
come up-regulated following stimulation with IL-33 or IL-
3 [16, 31–34]. In vitro stimulation with IL-33 promotes
basophil IgE-dependent and IgE-independent release of
histamine, and secretion of IL-4, IL-8, IL-5, IL-9, IL-6, IL-
13, MCP and MIP [16, 31–34]. IL-33 can induce human
basophil CD11b expression, adhesion and prime eotaxin-
induced migration, suggesting that IL-33 may regulate
basophil lung-homing [31]. Human basophils produce IL-
25 following IgE cross-linking and constitutively express
IL-17RB, which can be up-regulated following IL-3 stimu-
lation [35, 36]. Lastly, IL-25 can inhibit basophil apoptosis
and enhance IgE-mediated degranulation [36].
Despite IL-33 and IL-25 being identified as important
promoters of allergic inflammation in mouse models, the
influence of these cytokines on the effector role of baso-
phils in human allergic asthma needs to be further charac-
terized. Furthermore, little is known about the basophil
response to the airway microenvironment, including me-
diators released by the epithelium and other inflammatory
cells, following allergen inhalation. The purpose of this
study was to determine the relationship between basophils
and alarmin cytokines in human allergic asthma, and to
examine the basophil response to airway secretions fol-
lowing allergen inhalation in mild allergic asthmatics.
Methods
Allergen challenge study design
Ten subjects with mild allergic asthma underwent allergen
and diluent inhalation challenges separated by a two-week
wash out period (Table 1). All subjects had a positive skin
prick test (wheals > 2 mm) to common aeroallergens,
methacholine PC20 < 16 mg/mL, FEV1 of ≥70 % of pre-
dicted and a dual phase response to allergen (fall in FEV1
of ≥20 % by 2 h and ≥15 % 3–7 h post allergen). Subjects
used short-acting bronchodilators for control of asthma
and were excluded from the study if they were pregnant
or nursing, current smokers or ex-smokers with more
than 10 pack-years, or developed lower respiratory infec-
tions/exacerbations or used inhaled or oral steroids
4 weeks prior to study. Anti-histamines, caffeine and non-
steroidal anti-inflammatory agents were prohibited 48 h
before any study visit.
Baseline samples of peripheral blood, bone marrow as-
pirate and sputum samples were collected on day 1 and
subjects were randomized to diluent or allergen chal-
lenge on day 2. At 7 h post-challenge peripheral blood
and sputum was collected and at 24 h post-challenge
bone marrow, peripheral blood and sputum samples
were collected. AHR to allergen was measured by a shift
in methacholine PC20 measured before and 24 h after
challenge. Subjects returned after another two-week
wash out period to donate 100 mL of peripheral blood
for in vitro airway sample experiments.
Basophils for the in vitro experiments were purified
from 100 mL of peripheral blood of 8 donors, confirmed
to be allergic through positive skin prick testing to com-
mon aeroallergens. The study was approved by Hamilton
Integrated REB and all subjects provided signed in-
formed consent.
Methacholine challenge
The methacholine inhalation challenge was carried out
via tidal breathing from a Wright nebulizer, as previously
described [37]. In brief, doubling concentrations of
methacholine chloride (Methapharm, ON) were inhaled
Table 1 Subject Characteristics of Mild Allergic Asthmatics




M 61 96 Cat 1:32
F 24 80 Ragweed 1:16
M 52 95 HDM 1:64
F 40 104 Cat 1:128
M 25 86 Ragweed 1:8
F 24 93 HDM 1:8
M 26 93 HDM 1:32
M 20 94 Grass 1:4
F 34 70 Cat 1:512
M 26 96 Cat 1:8




F female, M male, HDM house dust mite. Data presented as mean ± SEM
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orally from a Hans Rudolph valve for 2 min. The FEV1
was measured following inhalation at 30 s and 90 s or
until it stopped falling. The percent fall was calculated
from the post-diluent FEV1 value. The test was termi-
nated when a fall in FEV1 of at least 20 % of the lowest
post-saline value occurred. The methacholine PC20 was
calculated using linear interpolation.
Allergen and diluent challenge
Allergen challenges were conducted by administering
inhaled doubling concentrations of aeroallergen ex-
tract, such as house dust mite, cat dander and pollen,
as previously described [38]. The extract giving the
largest skin wheal was selected for inhalation and the
concentration of allergen required to achieve a 20 %
decrease in FEV1 (the allergen PC20) was predicted
using the methacholine PC20 and skin test reactivity.
Diluent challenges were conducted using 3 inhalations
of 0.9 % saline for 2 min each. The EAR was the lar-
gest percent fall in FEV1 between 0 and 2 h, and the
LAR was the largest percent fall in FEV1 between 3
and 7 h post-challenge.
Bone marrow, blood, and sputum sample processing
During allergen and diluent inhalation challenges,
10 mL of peripheral blood was collected into sodium
heparin vaccutainers and 10 mL of bone marrow was as-
pirated from the iliac crest into heparin (1,000 U/mL).
To semi-isolate basophils from bone marrow, samples
were diluted in McCoys 5A, layered on Lymphoprep
and centrifuged at 2200 rpm for 20 min (min) at room
temperature (RT).
Sputum samples were induced using hypertonic saline
and mucous plugs were selected from samples followed
by dispersement with dithiothreitol, as previously de-
scribed [39]. Sputum samples were centrifuged at 790 g
4 °C for 10 min, followed by collection of supernatant,
additional centrifugation of the supernatant at 1500 g 4 °
C for 10 min, and aliquoting of supernatant into eppen-
dorfs that were frozen at −80 °C. Cytospins were pre-
pared from sputum cells and stained with Diff-Quik for
differential cell counts and toluidine blue for meta-
chromatic cell counts.
Commercially available multiplex immunoassay kits
were used to measure IL-33 and IL-25 (Bio-Rad labora-
tories, Inc, CA, US) in bone marrow, peripheral blood
and sputum samples collected pre and post-challenges.
Peripheral blood, bone marrow and sputum cells
were immunostained with isotype or specific mono-
clonal antibodies (mAbs) and acquired via flow cy-
tometry to identify basophils and measure the
percent cell expression of IL-17RB, ST2, and intracel-
lular IL-25 (all R&D Systems, MN, US) (Additional
file 1: Figure S1, Additional file 2: Figure S2 and
Additional file 3: Figure S3).
Purification of basophils for cell cultures
100 mL of blood was diluted with McCoys 5A media,
and layered on Lymphoprep. Erythrocytes were lysed
and basophils were purified via negative selection with
magnetic separation beads (Stem Cell Technologies, BC,
Canada). Basophil cell suspensions were >98 % pure as
determined by flow cytometry and >90 % viable by try-
pan blue (Additional file 4: Figure S4).
18 h Basophil Cultures with IL-25 and IL-33
Basophils purified from peripheral blood of 8 allergic
subjects were suspended in RPMI-C, then incubated for
18 h at 37 °C with monensin (Biolegend, CA, US), and
PBS, IL-3 (R&D Systems, MN, US), anti-IgE (Sigma,
MO, US), or a pre-determined optimal dose (Additional
file 5: Figure S5, Additional file 6: Figure S6) of IL-33 or
IL-25 (all 10 ng/mL) (R&D Systems, MN, US) and with
isotype controls or neutralizing antibodies to ST2 or IL-
17RB (both 10 μg/mL) (both R&D Systems, MN, US).
Basophils were immunostained with isotype or specific
mAbs to identify basophils (Additional 4: Figure S4) and
measure expression of CD203c (MACS Miltenyi, CA,
US), CCR3 (Ebioscience, CA, US), ST2 (Ebioscience,
CA, US), IL-17RB, TSLPR (Ebioscience, CA, US), as well
as intracellular IL-4 (Ebioscience, CA, US) and IL-13
(Ebioscience, CA, US) via flow cytometry.
Shape change assay with IL-33 and IL-25
To determine if IL-33 and IL-25 had a direct effect on
basophil shape change, purified basophils from allergic
donors (n = 8) suspended in RPMI-C were incubated
with PBS, IL-33 or IL-25 (both R&D Systems, MN, US)
(0.1, 1, 10, 100 ng/mL) at 37 °C for 0, 30, 45, 60 or
180 seconds (s). To determine if IL-33 or IL-25 primed
the basophil shape change response to eotaxin, purified
basophils were incubated for 18 h at 37 °C in RPMI-C
with PBS, IL-33 or IL-25 (all 10 ng/mL). Following
incubation, cells were stimulated with/without eotaxin
(R&D Systems, MN, US) (5 ng/mL) for 0, 30, 45, 60
or 180 s. Basophils were fixed with ice-cold 1 % PFA
for 10 min to stop the reaction and cell shape
change was measured by the parameter FSC via flow
cytometry.
18 h basophil cultures with airway samples
Purified basophils resuspended in RPMI-C collected from
the mild allergic asthmatic subjects were incubated for
18 h at 37 °C with monensin and sputum supernatant pre-
viously collected from allergen inhalations at baseline, 7
and 24 h post-challenge. To measure the effect of receptor
blockade, isolated basophils were treated with 10 μg/mL
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Table 2 Allergen inhalation induces airway inflammation in mild allergic asthmatics. Sputum cell count was measured pre and













Sputum Total Cell Count
(×104 cells/mL)
1.7 ± 1.2 1.5 ± 0.9 1.5 ± 0.8 1.8 ± 1.2 3.4 ± 2.9 3.1 ± 2.3a
Neutrophils (×104 cells/mL) 1.0 ± 1.3 1.2 ± 1.3 1.3 ± 1.4 0.9 ± 0.9 2.4 ± 2.3a 1.7 ± 1.3
Eosinophils (×104 cells/mL) 0.01 ± 0.0 0.02 ± 0.0 0.006 ± 0.0 0.02 ± 0.0 0.3 ± 0.4a 0.3 ± 0.4a
Metachromatic cells
(×104 cells/mL)
0 ± 0.0 0 ± 0.0 0 ± 0.0 0.01 ± 0.0 0.2 ± 0.3a 0.2 ± 0.2a
aSignificantly different than diluent control; P < 0.05
Fig. 1 Allergen-inhalation induces changes in surface receptor expression for alarmin cytokines on basophils of mild allergic asthmatics. Percent
of basophils expressing ST2, IL-17RB and intracellular IL-25 in 10 mild allergic asthmatics was measured in (a) bone marrow, (b) peripheral blood
and (c) sputum at pre-allergen, 7 h and 24 h post-allergen (black symbols), compared to diluent (open symbols). Data are presented as median ±
range. *Significantly different from pre-challenge for bone marrow and corresponding diluent-control time-point for peripheral blood and
sputum, † significantly different from 0 h; P < 0.05 (N = 10)
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isotype controls or neutralizing antibodies targeting the
βc, TSLPR, IL-17RB, and ST2 (all R&D Systems, MN,
US). Incubation with PBS served as the negative con-
trol, and incubation with 10 ng/mL IL-3 was the
positive control. Basophils were immunostained to
identify the basophil population and to measure both
CD203c and intracellular expression of IL-13 and IL-
4 by flow cytometry.
Flow cytometry staining and analysis
Cells for flow cytometry experiments were immuno-
stained with isotype or specific mAbs to the extracellular
CD45 (Ebioscience, CA, US), HLA-DR (Ebioscience,
CA, US), CCR3, TSLPR, IL-3Rα (Ebioscience, CA, US)
and CD203c for 30 min at 4 °C. To measure intracellular
cytokine expression, cells were washed, fixed and perme-
abilized, then stained with isotype controls or antibodies
to IL-4, IL-13 and IL-25. Cells were washed and ac-
quired with a LSR II flow cytometer (BD Biosciences,
CA, US). Analyses were performed using Flow-Jo
software (Tree Star, CA, US). Basophils were defined
as the CD45+/HLA-DR−/IL-3Rα+ population, as out-
lined in Additional files 1, 2, 3 and 4. The isotype
control for the markers of interest was set to 2 %,
which was compared to the specific markers to detect
the percentage of cells expressing the marker.
Statistical analysis
All data are presented as mean ± SEM except for flow
cytometry data which are expressed as median percent
positive cells. Statistical analysis for inhalation challenges
was performed using 2-way ANOVA and post-hoc Bon-
ferroni test. In vitro experiments were analyzed using 1-
way ANOVA with a post-hoc Tukey test. Correlation
analyses were conducted using a Spearman correlation
test. Significance was accepted at P < 0.05.
Results
Allergen inhalation induces airway bronchoconstriction,
hyperresponsiveness and inflammation mild allergic
asthmatics
Inhalation of allergen induced a maximum fall in FEV1
of 20.1 ± 5.5 % within the first 2 h, and a maximum fall
in FEV1 of 20.8 ± 5.2 % 3–7 h post-challenge, compared
to no change in FEV1 following diluent inhalation. The
methacholine PC20 decreased one doubling dose post-
allergen challenge, compared to no change post-diluent.
Compared to diluent, the allergen inhalation challenge
induced a significant increase in the sputum total cell
count and number of granulocytes (Table 2). IL-25 could
be detected in the bone marrow of 2 subjects, peripheral
blood of 7 subjects, and sputum of 3 subjects. IL-33
could be detected in the bone marrow of 6 subjects, per-
ipheral blood of 4 subjects and sputum of 3 subjects.
We found no significant change in IL-25 or IL-33 levels
in bone marrow, peripheral blood or sputum after aller-
gen challenge (data not shown). The measurable levels
of IL-25 or IL-33 showed no correlation with allergen-
induced change in AHR to methacholine or maximum
fall in FEV1.
Allergen inhalation induces changes in basophil
expression of IL-17RB and ST2
In bone marrow, there was a significant increase in the
percentage of basophils expressing IL-17RB and ST2 at
24 h post-allergen challenge compared to baseline
(Fig. 1a). In the peripheral blood we observed a signifi-
cant increase in the percentage of basophils expressing
IL-17RB at 7 h post-allergen and ST2 at 7 and 24 h
post-allergen, compared to diluent (Fig. 1b). The per-
centage of peripheral blood basophils expressing ST2 at
7 and 24 h post-allergen was significantly greater com-
pared to baseline (Fig. 1c). The percentage of sputum
basophils expressing IL-17RB increased significantly at
24 h post-allergen, whereas no change was found with
Fig. 2 Correlation between ST2 basophil expression and lung function following allergen challenge in mild allergic asthmatics. Percent peripheral
blood basophil expression in 10 mild allergic asthmatics of (a) ST2 at 7 h post-allergen compared to LAR, (b) ST2 at 24 h post-allergen compared
to LAR. *Significant correlation between basophil ST2 expression and lung function; P < 0.05 (N = 10)
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respect to ST2, compared to diluent (Fig. 1). Percentage
of basophils expressing intracellular levels of IL-25 in-
creased at 24 h post-allergen in peripheral blood and
remained elevated for up to 24 h post-allergen in the
sputum, compared to diluent (Fig. 1). Allergen did
not change the percentage of basophils expressing
intracellular IL-25 in the bone marrow. We observed
a significant positive correlation between allergen-
induced maximum % fall FEV1 3–7 h and percentage
of peripheral blood basophils expressing ST2 mea-
sured 24 h post-allergen (P = 0.015, R = 0.75) (Fig. 2b).
No relationship was found between allergen-induced
methacholine PC20 and peripheral blood ST2, IL-
17RB or intracellular IL-25 basophil expression.
Lastly, no correlation was found between airway ST2,
IL-17RB or intracellular IL-25 basophil expression
and lung function (methacholine PC20; LAR FEV1).
Basophils express functional receptors for IL-33 and IL-25
Basophils from allergic subjects expressed IL-17RB and
ST2, and stimulation with IL-3 and anti-IgE significantly
increased the percentage of basophils expressing these
receptors (Fig. 3a, b). Stimulation with IL-25 and IL-33
markedly up-regulated the percentage of basophils ex-
pressing receptors for these cytokines, IL-17RB and ST2,
respectively (Fig. 3a, b). IL-25 had no effect on percent
cell expression of ST2, nor did IL-33 affect IL-17RB
(Fig. 3b). IL-25 and IL-33 had no effect on TSLPR ex-
pression, however TSLP increased the percentage of ba-
sophils expressing IL-17RB and ST2 (Fig. 3c).
IL-33 and IL-25 exert pro-inflammatory effects on
basophils
We examined the effect of 18 h incubation with IL-
25 and IL-33 on markers of basophil activation and
observed a significantly higher percentage of basophils
expressing intracellular IL-4 and IL-13, as well as
CD203c (Fig. 4). The level of IL-3Rα basophil expres-
sion increased, as shown by significant shift in the
sMFI (Fig. 4). The aforementioned measurements sig-
nificantly decreased following treatment with neutral-
izing antibodies to IL-17RB and ST2.
IL-25 and IL-33 prime basophil migratory potential in
response to eotaxin
Compared to PBS negative control, incubation with IL-
33 and IL-25 for 18 h induced significant up-regulation
of CCR3 expression on basophils, as shown by a shift in
the sMFI (Fig. 5a). IL-33 and IL-25 did not directly
stimulate basophil shape change (data not shown), how-
ever overnight incubation with IL-25 and IL-33 induced
greater shape change in response to stimulation with
eotaxin (Fig. 5b, c). The priming effect was observed by
45 s following eotaxin stimulation and maintained for
up to 180 s, and treatment with neutralizing anti-
bodies to IL-17RB and ST2 significantly inhibited the
priming effects of IL-33 and IL-25 on eotaxin-
induced basophil shape change compared to the iso-
type control (Fig. 5d, e).
Sputum supernatant samples collected post-allergen
inhalation induce basophil activation
Commercial multiplex immunoassays were unable to de-
tect a complete data set of IL-33 and IL-25 levels in
Fig. 3 IL-25 and IL-33 up-regulate expression of their own receptor on
basophils. Purified peripheral blood basophils from 8 allergic donors
were suspended in RPMI-C and cultured for 18 h with PBS or optimal
concentrations of anti-IgE, IL-3, TSLP, IL-25, or IL-33 (all 10 ng/mL), then
assessed for percent basophil expression of (a) IL-17RB, (b) ST2, and (c)
TSLPR. Data are expressed as mean ± SEM. *Significantly different from
PBS negative control; P < 0.05 (N = 8)
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airway samples. As a result, we used an alternative bio-
assay to evaluate the in vitro effect of airway secretions
collected after allergen inhalation on basophil activation.
Airway samples collected 7 h post-allergen had the
greatest effect on basophil activity as shown by increased
percentage of basophils expressing CD203c, and intra-
cellular IL-4 and IL-13 compared to PBS negative con-
trol and 0 h samples (Fig. 6a). There was no difference
between the effect of IL-3 (positive control) and 7 h
post-allergen airway samples on the percentage of baso-
phils expressing CD203c and intracellular IL-4 and IL-
13. Incubation with 0 h airway samples significantly
increased the percentage of basophils expressing
CD203c and intracellular IL-4 (Fig. 6a, b), whereas 24 h
airway samples increased basophil percent expression of
intracellular IL-4 (Fig. 6b).
To ascertain the mechanisms through which the
airway microenvironment promotes basophil activa-
tion post-allergen inhalation, we determined whether
airway sample-induced basophil activation could be
inhibited following treatment with neutralizing anti-
bodies to the βc for IL-3/IL-5/GM-CSF, and the re-
ceptors for alarmin cytokines ST2, and IL-17RB.
Blockade of the βc significantly inhibited basophil ac-
tivation induced by 7 h post-allergen airway samples
(Fig. 7). Treatment with neutralizing antibodies to TSLPR
(Fig. 7a), ST2 (Fig. 7b), or IL-17RB (Fig. 7b) alone did not
inhibit the stimulatory effects of 7 h post-allergen airway
samples on markers of basophil activation. The addition
of the anti-βc with anti-TSLPR, anti-ST2, or anti-IL-17RB
significantly inhibited the stimulatory effects, but there
was no synergistic effect (Fig. 7).
Discussion
Previous studies have shown that basophils express ST2,
and this can be up-regulated following in vitro stimula-
tion with IL-33 or IL-3 [16, 31–34, 36]. We expanded on
these findings by demonstrating that IL-25 and IL-33
up-regulated their own receptors on basophils. Interest-
ingly, IL-3, anti-IgE, and TSLP stimulation up-regulated
percent basophil expression of IL-17RB and ST2, how-
ever IL-25 and IL-33 had no effect on TSLPR,
Fig. 4 The effects of IL-25 and IL-33 on markers of basophil activation.
Purified peripheral blood basophils from 8 allergic donors were
incubated for 18 h with or without IL-25 or IL-33 (both 10 ng/mL)
and neutralizing antibodies for IL-17RB and ST2 or isotype controls
(both 10 μg/mL). Receptor blockade (light grey bars) was assessed by
comparison to isotype controls (black bars) via measuring: (a) CD203c,
(b) IL-3Rα, (c) intracellular IL-13, and (d) intracellular IL-4. Anti-IgE and
IL-3 (10 ng/mL) served as positive controls (dark grey bars). Data
are expressed as mean ± SEM. *Significantly different from PBS
negative control, † significantly different from isotype control
P < 0.05 (N = 8)
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suggesting that these cytokines act downstream of TSLP.
We have shown that the sensitivity of basophils to IL-33
and IL-25 can be up-regulated through both IgE-
dependent or IgE-independent mechanisms.
Other studies have reported that IL-33 and IL-25 in-
duce pro-inflammatory effects on human basophil activ-
ity [16, 31–34, 36]. IL-25 inhibits basophil apoptosis and
promotes IgE-mediated degranulation, but does not in-
duce IL-4 or IL-13 release [36], whereas IL-33 promotes
basophil Type 2 cytokine production [16, 31–34]. Al-
though Wang et al. did not find that IL-25 induced
basophil Type 2 cytokine release, we observed an in-
crease in percent basophil expression of intracellular IL-
4 and IL-13. Discrepancies between these studies may be
Fig. 5 IL-25 and IL-33 prime eotaxin-induced basophil shape change. Purified peripheral blood basophils from 8 allergic donors were suspended
in RPMI-C and incubated with/without IL-25 and IL-33 (10 ng/mL) to assess (a) CCR3 expression and (b, c) shape change was measured via
change in FSC post-stimulation with eotaxin (5 ng/mL). The effect of neutralizing antibodies for (d) IL-17RB and (e) ST2 (light grey bars) on shape
change was also assessed. Data are expressed as mean ± SEM. ‡ Significantly different from eotaxin, *significantly different from PBS negative
control, † significantly different from isotype control; P < 0.05 (N = 8)
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due to differences in time-points and methodologies.
We confirm previous reports that overnight incubation
of basophils with IL-33 increased the percent basophil
expression of intracellular IL-4 and IL-13, but also
showed up-regulation of IL-3Rα and CD203c expression.
IL-25 and IL-33-induced basophil activity was inhibited
following blockade of IL-17RB and ST2, demonstrating
the effects of these cytokines are, in part, mediated dir-
ectly through their own receptors.
Suzukawa et al. previously demonstrated that stimula-
tion with IL-33 could enhance basophil migration to-
wards eotaxin [33], however no studies have thus far
have shown an effect of IL-25 on basophil migration.
Using shape change as a surrogate marker for migration,
as previously described [28, 29], we demonstrated that
IL-25 and IL-33 prime basophil migratory potential to
eotaxin through up-regulation of CCR3 expression. Con-
versely, Suzukawa et al. found no increase in basophil
CCR3 expression following 1 h stimulation with IL-33,
whereas we found that overnight IL-33 stimulation up-
regulated CCR3 expression. Variation between these
findings could be due to different stimulation time-
points used. We have previously shown that following
allergen inhalation, bone marrow basophils decrease in
CCR3 expression at 24 h post-allergen, whereas CCR3
expression was up-regulated on both peripheral blood
and sputum basophils [28]. Taken together with in-
creased sputum basophil numbers post-allergen, this
suggests that a subset of activated basophils express-
ing CCR3 influx to the lungs in response to eotaxin
post-allergen challenge. This coincides with mecha-
nisms of eosinophil migration from the bone marrow
[40], with elevated peripheral eotaxin levels by 5 h
post-allergen challenge [41] and with our findings that
IL-25 and IL-33 up-regulate CCR3 basophil expres-
sion after overnight incubation.
Most importantly, we have shown up-regulation of
percent basophil expression for IL-17RB within the bone
marrow, peripheral blood and airways, as well as ST2
within the bone marrow and peripheral blood post-
allergen challenge. These findings are similar to our pre-
vious reports that the percentage of basophils expressing
TSLPR increases following allergen inhalation for up to
24 h [28]. Moreover, 24 h post-allergen percent basophil
expression of ST2 positively correlated with allergen-
induced bronchoconstriction. This is similar to our pre-
vious reports that peripheral blood percent basophil
expression of TSLPR correlates with maximal % FEV1
fall during the LAR [28]. These findings suggest that
interaction between basophils and alarmin cytokines, in-
cluding TSLP, may be a contributing factor to declined
lung function during the LAR. Basophils have been iden-
tified as a source of IL-25 following IgE cross-linking
[35], and we found intracellular IL-25 expression to be
elevated within the periphery and sputum post-allergen,
which may further contribute to Type 2 inflammation.
In contrast, we found no change in sputum percent
basophil expression of ST2 following allergen challenge.
We propose that this may be due to asthmatic subjects
Fig. 6 The effects of airway samples on markers of basophil
activation. Purified peripheral blood basophils from 8 mild allergic
asthmatic subjects were suspended in RPMI-C and cultured for 18 h
with PBS as negative control (open bars) or IL-3 (10 ng/mL) as
positive control (dark grey bars) or sputum supernatant collected
from dual responders at 0 h, 7 h, and 24 h post-allergen (black bars)
then measured for expression of (a) CD203c, (b) IL-4, and (c) IL-13.
Data expressed as mean ± SEM. *Significantly different from PBS
negative control; P < 0.05 (N = 8)
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already having elevated ST2 expression pre-challenge
due to the underlying disease, thereby making it difficult
to detect changes in airway basophil expression. This
is, in part, supported by Pecaric-Petkovic et al. who
demonstrated that non-stimulated basophils in normal
subjects had no detectable levels of ST2, but stimula-
tion with IL-3 induced measurable levels [31]. More-
over, we have shown that a correlation between
peripheral blood basophil ST2 expression and LAR
bronchoconstriction.
The final component of this study was to examine baso-
phil responsiveness to samples collected from the airway
microenvironment during the LAR, containing mediators
released by the epithelium and other inflammatory cells.
Overnight incubation of isolated human basophils with
7 h post-allergen sputum supernatant yielded the greatest
increase in percent basophil expression of CD203c, and
intracellular IL-13 and IL-4. The 0 h airway samples also
induced significant increases in percent cell expression of
CD203c and intracellular IL-4, supporting the notion that
allergic asthmatics have underlying Type 2 inflammation
in the airways compared to healthy individuals. Collect-
ively, these findings demonstrate that following allergen
inhalation, the airway microenvironment can up-regulate
activation markers on basophils. Blockade of βc led to in-
hibition of basophil activation induced by 7 h airway
Fig. 7 Blocking βc neutralizes the effects of airway samples on basophils. Purified peripheral blood basophils from 16 mild allergic asthmatic
subjects were suspended in RPMI-C and cultured for 18 h with PBS as negative control (open bars) or 7 h post-allergen sputum supernatant and
neutralizing antibodies to (a) TSLPR, (b) ST2 or IL-17RB, and (a, b) βc (10 μg/mL) (light grey bars) on markers of basophil function by expression of
CD203c, IL-4, and IL-13. Data expressed as mean ± SEM. IL-3 (10 ng/mL) served as positive control (dark greys bars) *Significantly different from
PBS negative control, † significantly different from isotype control (open bars); P < 0.05 (N = 8)
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samples, whereas neutralization of receptors for alarmin
cytokines had no inhibitory effect.
Murine models have shown that knock out of TSLPR,
IL-17RB, or ST2 reduces AHR and eosinophilia, how-
ever blockade of these receptors in our experiments had
no effect on basophil pro-inflammatory activity induced
by airway samples. We have had difficulty detecting
TSLP, IL-33 and IL-25 protein in sputum samples [28]
and this may be due to alarmin cytokines being unstable
and metabolized quickly, thus requiring more sensitive
assays for measurement [42]. Previous studies have dem-
onstrated that airway IL-33 and IL-25 mRNA expression
is increased in asthmatics [23–26]. Furthermore, Fux et
al. reported that IL-33 protein increases rapidly in BALF
after allergen challenge, but declines to baseline levels at
18 h post-allergen [43]. It is possible that although alar-
min cytokines are upstream triggers of Type 2 inflam-
mation during the EAR, their levels may not be
significant during the LAR. Downstream Type 2 cyto-
kines such as IL-3, IL-5 and GM-CSF, may be more
prevalent within the airways during the LAR. Therefore,
blockade of βc has a more profound inhibitory effect on
basophil activation in vitro, as opposed to epithelial-
derived cytokine receptor neutralization. Lastly, baso-
phils are known to have an IL-3 autocrine activation
loop. We have previously reported that TSLP can induce
basophil production of IL-3, which could in turn serve
as another mechanism for TSLP to enhance basophil ac-
tivation by signaling through IL-3Rα [28]. In this study
we have demonstrated that IL-25 and IL-33-induced
basophil activation was inhibited following blockade of
IL-17RB and ST2, however, we cannot rule out the pos-
sibility that the effects of IL-25 and IL-33 may be medi-
ated in an IL-3/IL-5/GM-CSF-dependent manner.
Whether or not IL-25 and IL-33 exert their effects add-
itionally through an IL-3 dependent mechanism will
need to be elucidated further in the future.
We could not detect levels of IL-13 or IL-4 released
from basophils due to the low numbers of cells utilized
in these in vitro experiments. Instead, we measured
intracellular cytokine expression through flow cytome-
try, however demonstrating intracytoplasmic expression
of IL-13 and IL-4 cannot indicate whether these proteins
are actually released [41]. Due to limited basophil
numbers, migration experiments typically using trans-
well migration were replaced with cell shape change
as a surrogate measure of migration [44]. Although
this is not the traditional method of determining
migration, shape change is an effective way to assess
migratory potential.
Conclusion
In summary, we demonstrate that allergen inhalation in-
creases airway basophil numbers and their sensitivity to
IL-25 and IL-33 through up-regulation of the percentage
of basophils expressing surface IL-17RB and ST2.
Furthermore, markers of basophil activation signifi-
cantly increase post-allergen in response to the airway
microenvironment through an IL-3-dependent mech-
anism, which may be in part due to stimulation by
IL-25 and IL-33. We conclude that basophil responses
to these alarmin cytokines play an important role in
potentiating Type 2 inflammation and serves as a
novel therapeutic target for the treatment of allergic
asthma.
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Additional file 1: Figure S1. Bone marrow basophil gating strategy
and change in marker expression. Representative bone marrow dot plots
showing basophil gating strategy used for flow cytometry analysis
including: (A) Side Scatter (SSC) vs. Forward Side Scatter (FSC), (B) SSC vs.
CD45 Alexa Fluor 700, (C) SSC vs. HLA-DR APCH7 and (D) SSC vs. IL-3Rα
PECy7. Panels E-G are representative dot plots of the change in the
percentage of basophils expressing IL-17RB, ST2, and intracellular IL-25 at
pre-allergen challenge (blue) and 24 h post-allergen challenge (green),
compared to the isotype control (red). (TIFF 10587 kb)
Additional file 2: Figure S2. Peripheral blood basophil gating strategy
and change in marker expression. Representative peripheral blood dot
plots showing basophil gating strategy used for flow cytometry analysis
including: (A) SSC vs. FSC, (B) SSC vs. CD45 Alexa Fluor 700, (C) SSC vs.
HLA-DR APCH7 and (D) SSC vs. IL-3Rα PECy7. Panels E-G are representative
dot plots of the change in the percentage of basophils expressing IL-17RB,
ST2, and intracellular IL-25 at pre-allergen challenge (blue), 7 h post-allergen
(green) and 24 h post-allergen challenge (orange), compared to the isotype
control (red). (TIFF 9034 kb)
Additional file 3: Figure S3. Sputum basophil gating strategy and
change in marker expression. Representative sputum dot plots showing
basophil gating strategy used for flow cytometry analysis including: (A)
Side Scatter (SSC) vs. Forward Side Scatter (FSC), (B) SSC vs. CD45 Alexa
Fluor 700, (C) SSC vs. HLA-DR APCH7 and (D) SSC vs. IL-3Rα PECy7. Panels
E-G are representative dot plots of the change in the percentage of
basophils expressing IL-17RB, ST2, and intracellular IL-25 at pre-allergen
challenge (blue), 7 h post-allergen (green) and 24 h post-allergen challenge
(orange), compared to the isotype control (red). (TIFF 10198 kb)
Additional file 4: Figure S4. Purified basophil gating strategy for in
vitro cultures. Representative dot plots demonstrating gating strategy
used for flow cytometry analysis of purified basophils including: (A) SSC
vs. CD45 Alexa Fluor 700 (B) SSC vs. HLA-DR APCH7 and (C) SSC vs. IL-
3Rα PECy7. Purified basophil populations had a mean purity of >98 %.
(TIFF 3300 kb)
Additional file 5: Figure S5. Basophil activation marker dose response
to IL-33. Isolated peripheral blood basophils from 8 allergic subjects were
suspended in RPMI-C and cultured for 18 h with PBS (negative control,
open bars) or increasing concentrations of IL-33 (0.1, 1, 10, 100 ng/mL)
(black bars), were assessed for expression of (A) CD203c, (B) IL-3Rα, (C)
CCR3, (D) intracellular IL-13, (E) intracellular IL-4, (F)
intracellular IL-25, (G) IL-17RB, (H) ST2, and (I) TSLPR. Data expressed
as mean ± SEM. *Significantly different from PBS negative control;
P < 0.05 (N = 8). (TIFF 2756 kb)
Additional file 6: Figure S6. Basophil activation marker dose response
to IL-25. Isolated peripheral blood basophils from 8 allergic subjects were
suspended in RPMI-C and cultured for 18 h with PBS (negative control,
open bars) or increasing concentrations of IL-25 (0.1, 1, 10, 100 ng/mL)
(black bars), were assessed for expression of (A) CD203c, (B) IL-3Rα, (C)
CCR3, (D) intracellular IL-13, (E) intracellular IL-4, (F) intracellular IL-25, (G)
IL-17RB, (H) ST2, and (I) TSLPR. Data expressed as mean ± SEM.
*Significantly different from PBS negative control; P < 0.05 (N = 8).
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